| Identification | Back Directory | [Name]
TMP269 | [CAS]
1314890-29-3 | [Synonyms]
TMP269
CS-1345
TMP269, >=98%
TMP 269; TMP-269
N-((4-(4-Phenylthiazol-2-yl)tetrahydro-2H-pyran-4-yl)methyl)-3-(5-(trifluoromethyl)-1,2,4-oxad
N-{[4-(4-phenyl-1,3-thiazol-2-yl)oxan-4-yl]methyl}-3-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide
N-((4-(4-phenylthiazol-2-yl)tetrahydro-2H-pyran-4-yl)Methyl)-3-(5-(trifluoroMethyl)-1,2,4-oxadiazol-3-yl)benzaMide
N-[[Tetrahydro-4-(4-phenyl-2-thiazolyl)-2H-pyran-4-yl]methyl]-3-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide
BenzaMide, N-[[tetrahydro-4-(4-phenyl-2-thiazolyl)-2H-pyran-4-yl]Methyl]-3-[5-(trifluoroMethyl)-1,2,4-oxadiazol-3-yl]-
N-{[4-(4-phenyl-1,3-thiazol-2-yl)tetrahydro-2h-pyran-4-yl]methyl} -3-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide
N-[[Tetrahydro-4-(4-phenyl-2-thiazolyl)-2H-pyran-4-yl]methyl]-3-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide TMP269
TMP269 N-[[Tetrahydro-4-(4-phenyl-2-thiazolyl)-2H-pyran-4-yl]methyl]-3-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide | [Molecular Formula]
C25H21F3N4O3S | [MDL Number]
MFCD26522023 | [MOL File]
1314890-29-3.mol | [Molecular Weight]
514.52 |
| Chemical Properties | Back Directory | [density ]
1.347±0.06 g/cm3(Predicted) | [storage temp. ]
Amber Vial, -20°C Freezer, Under inert atmosphere | [solubility ]
≥23 mg/mL in DMSO; insoluble in H2O; ≥21 mg/mL in EtOH with ultrasonic | [form ]
solid | [pka]
13.66±0.46(Predicted) | [color ]
White to off-white | [SMILES]
FC(F)(C1=NC(C2=CC(C(NCC3(C4=NC(C5=CC=CC=C5)=CS4)CCOCC3)=O)=CC=C2)=NO1)F |
| Hazard Information | Back Directory | [Uses]
TMP269 is a selective class IIa histone deacetylase (HDAC) inhibitor via a non chelating zinc-binding group. | [Biological Activity]
tmp269 is a novel and selective inhibitor of class iia histone deacetylase with ic50 values of 126, 80, 36, 9 nm for hdac 4, 5, 7, 9, respectively [1].histone deacetylases (hadc) are a series of enzymes that remove acetyl groups from an ε-n-acetyl lysine amino acid on a histone and make the histones to wrap the dna more tightly, which prevent transcription.tmp269 is a novel and selective class iia hdac inhibitor. in mm cell lines, tmp269 induced modest cytotoxicity with ic50 values ranging from 22 to 38 μm in a dose-dependent way, which was associated with cleavage of caspase-3, -8, -9 and parp. also, tmp269 enhanced cfz-induced apoptosis and increased the expression of activating transcription factor 4 (atf4) and proapoptotic transcription factor c/ebp homologous protein (chop). in the presence of bmscs or il-6, tmp269 and cfz also showed significant cytotoxicity [2]. in iec-18 intestinal epithelial cells, tmp269 inhibited cell proliferation, cell cycle progression and dna synthesis in response to g protein-coupled receptor/protein kinase d1 (pkd1) activation [3]. | [in vivo]
In vivo angiogenesis assay, MDA-MB-231 cells are mixed with growth factor-reduced Matrigel and implanted subcutaneously into the flanks of nude mice. TMP269 (subcutaneous injection; 15 mg/kg; every other day; 10 days) shows an obvious antiangiogenic effect with 76% inhibition of angiogenesis in mice[4]. | [target]
HDAC9 | [IC 50]
HDAC9: 23 nM (IC50); HDAC7: 43 nM (IC50); HDAC5: 97 nM (IC50); HDAC4: 157 nM (IC50); HDAC8: 42000 nM (IC50); HDAC6: 82000 nM (IC50) | [References]
[1]. lobera m, madauss kp, pohlhaus dt, et al. selective class iia histone deacetylase inhibition via a nonchelating zinc-binding group. nat chem biol, 2013, 9(5): 319-325.
[2]. kikuchi s, suzuki r, ohguchi h, et al. class iia hdac inhibition enhances er stress-mediated cell death in multiple myeloma. leukemia, 2015.
[3]. sinnett-smith j, ni y, wang j, et al. protein kinase d1 mediates class iia histone deacetylase phosphorylation and nuclear extrusion in intestinal epithelial cells: role in mitogenic signaling. am j physiol cell physiol, 2014, 306(10): c961-71. |
|
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
|